KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ: 307750)
South Korea
· Delayed Price · Currency is KRW 3,465.00
-135.00 (-3.75%)
Dec 20, 2024, 9:00 AM KST
KUKJEON PHARMACEUTICAL Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | 6,592 | 4,824 | 8,948 | 4,038 |
| Depreciation & Amortization | 4,896 | 3,134 | 1,444 | 1,106 |
| Loss (Gain) From Sale of Assets | 8.36 | - | 69.18 | 0 |
| Loss (Gain) From Sale of Investments | -1,272 | -16.28 | -373.28 | -0.86 |
| Loss (Gain) on Equity Investments | 50.44 | -1.15 | 4.35 | 276.83 |
| Provision & Write-off of Bad Debts | -15.36 | -9.72 | -3.06 | 113.92 |
| Other Operating Activities | -4,022 | 2,130 | -9,299 | 753.65 |
| Change in Accounts Receivable | 3,578 | -6,493 | -2,128 | -3,916 |
| Change in Inventory | 3,746 | -7,203 | -3,541 | -3,813 |
| Change in Accounts Payable | 1,791 | 3,406 | -670.22 | 5,448 |
| Change in Other Net Operating Assets | -2,751 | -115.82 | -470.41 | -964.89 |
| Operating Cash Flow | 12,601 | -345.45 | -6,019 | 3,042 |
| Capital Expenditures | -9,515 | -43,923 | -23,285 | -10,409 |
| Sale of Property, Plant & Equipment | - | - | 2.09 | - |
| Cash Acquisitions | 96.04 | - | 295.92 | - |
| Divestitures | 441 | 441 | - | - |
| Sale (Purchase) of Intangibles | -3,595 | -157.99 | -482.07 | -8.8 |
| Investment in Securities | -13,238 | 18,410 | -53,176 | -22,097 |
| Other Investing Activities | -317.43 | 584.15 | 25.38 | 69.36 |
| Investing Cash Flow | -25,797 | -24,314 | -76,633 | -32,579 |
| Short-Term Debt Issued | - | 35,734 | 101,363 | 27,327 |
| Long-Term Debt Issued | - | 8,000 | 18,562 | - |
| Total Debt Issued | 65,904 | 43,734 | 119,925 | 27,327 |
| Short-Term Debt Repaid | - | -28,338 | -33,395 | -33,653 |
| Long-Term Debt Repaid | - | -1,690 | -933.22 | -293.8 |
| Total Debt Repaid | -51,126 | -30,028 | -34,329 | -33,947 |
| Net Debt Issued (Repaid) | 14,779 | 13,706 | 85,596 | -6,620 |
| Issuance of Common Stock | - | - | - | 45,477 |
| Repurchase of Common Stock | -100 | - | - | -1.03 |
| Dividends Paid | -490.69 | - | -490.69 | - |
| Other Financing Activities | -1,220 | 400 | -5.6 | -0 |
| Financing Cash Flow | 12,968 | 14,106 | 85,100 | 38,856 |
| Foreign Exchange Rate Adjustments | -0.49 | -0.26 | -0.34 | 0.13 |
| Net Cash Flow | -228.21 | -10,554 | 2,447 | 9,320 |
| Free Cash Flow | 3,086 | -44,269 | -29,304 | -7,367 |
| Free Cash Flow Margin | 2.30% | -36.29% | -28.26% | -8.63% |
| Free Cash Flow Per Share | 62.89 | -902.17 | -571.94 | -167.01 |
| Cash Interest Paid | 1,750 | 1,373 | 771.53 | 238.65 |
| Cash Income Tax Paid | 252.52 | -115.43 | 1,625 | 518.27 |
| Levered Free Cash Flow | -561.65 | -40,786 | -10,027 | - |
| Unlevered Free Cash Flow | 4,440 | -37,202 | -8,901 | - |
| Change in Net Working Capital | -11,432 | 322.63 | -11,243 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.